Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Best Practice & Research. Clinical Obstetrics & Gynaecology|December 7, 2018
Unexplained infertility: Is it over-diagnosed and over-treated?Ben W Mol, Raissa Tjon-Kon-Fat, Esmé Kamphuis, et al.The British Journal of Dermatology|May 12, 2023
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept studyAngelique N Voorberg, Esmé Kamphuis, Wietske A Christoffers, et al.Contact Dermatitis|January 9, 2023
Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registryEsmé Kamphuis, Laura Loman, Henry L Han, et al.Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|December 24, 2022
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.Acta Dermato-Venereologica|February 7, 2024
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay RegistryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.Acta Dermato-Venereologica|November 24, 2022
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay RegistryCeleste M Boesjes, Esmé Kamphuis, Nicolaas P A Zuithoff, et al.JAMA Dermatology|October 16, 2024
Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic DermatitisLisa P van der Rijst, Esmé Kamphuis, Marie L A Schuttelaar, et al.The British Journal of Dermatology|May 13, 2023
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryLotte S Spekhorst, Celeste M Boesjes, Laura Loman, et al.Journal of the American Academy of Dermatology|April 23, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJunfen Zhang, Celeste M Boesjes, Laura Loman, et al.JAMA Dermatology|August 7, 2024
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic DermatitisCeleste M Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.Pageof 1